This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignees: Hangzhou Pushai Pharmaceutical Technology Co., Ltd., Hangzhou Solipharma Co., Ltd.. Active years: 2017-2021.
Location History:
- Hangzhou, CN (2017)
- Zhejiang, CN (2019 - 2021)
Company Filing History:
2 out of 8 
1 out of 19 Years Active: 2017-2021
Title: Innovations of Xiaoye Song in Pharmaceutical Development
Introduction
Xiaoye Song is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of 3 patents, his work focuses on improving the stability and efficacy of medications.
Latest Patents
One of Xiaoye Song's latest patents is titled "Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof." This invention relates to canagliflozin monohydrate and its crystalline forms, which exhibit higher stability in water or aqueous systems compared to prior art. These forms are more suitable for wet granulation processes or suspension preparations and demonstrate good storage stability. The invention also encompasses preparation methods for canagliflozin monohydrate, pharmaceutical compositions, and their applications in treating diseases such as diabetes, diabetes complications, and obesity.
Career Highlights
Xiaoye Song has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Hangzhou Pushai Pharmaceutical Technology Co., Ltd. and Hangzhou Solipharma Co., Ltd. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Throughout his career, Xiaoye Song has collaborated with various professionals in the field. Some of his notable coworkers include Xiaoxia Sheng and Xiaohong Sheng, who have also contributed to advancements in pharmaceutical technologies.
Conclusion
Xiaoye Song's innovative work in the pharmaceutical sector, particularly with canagliflozin monohydrate, showcases his commitment to improving drug formulations for better patient outcomes. His contributions continue to influence the development of effective treatments for chronic diseases.